Research Methods & Ethics · 1962
Kefauver-Harris Drug Amendments
Drug Amendments of 1962 (Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act)
By the late 1950s, Senator Estes Kefauver of Tennessee was already pressing for drug industry reform on antitrust and pricing grounds when the thalidomide crisis supplied a different and more urgent argument. Thalidomide, marketed in Europe as a sedative and treatment for morning sickness, caused severe limb malformations in thousands of children born to mothers who took it during the first trimester. It had not been approved in the United States, largely because Frances Kelsey, an FDA reviewer, had repeatedly demanded safety data the manufacturer could not produce. The legislation that followed drew its political force from that near-miss.
Passed in October 1962, the Kefauver-Harris amendments overhauled the Federal Food, Drug, and Cosmetic Act in two fundamental ways. First, manufacturers now had to demonstrate efficacy through adequate and well-controlled studies before approval, not merely safety. That requirement, which had never appeared in federal law before, effectively mandated the randomized controlled trial as the evidentiary standard for new drugs. Second, subjects enrolled in clinical research had to give informed consent, extending to pharmaceutical trials the principle the Nuremberg Code had articulated for wartime experimentation.
Kelsey received the President's Award for Distinguished Federal Civilian Service in 1962, the same year the amendments passed. The standard she had applied as an individual reviewer, demanding rigorous evidence rather than accepting manufacturer assurances, now had the force of law. The FDA simultaneously received authority to regulate trial design and not just review completed results, a power that would eventually produce detailed guidance on control arms, blinding, and endpoint selection.
The requirement for controlled evidence had immediate consequences for drugs already on the market. The FDA launched a retrospective review of approximately 4,000 drugs approved between 1938 and 1962 on safety grounds alone; most lacked efficacy data meeting the new standard. That effort, conducted partly through the National Academy of Sciences, resulted in the withdrawal of hundreds of preparations that could not demonstrate benefit.
The amendments established the regulatory architecture in which the pharmaceutical industry still operates. Phase I, II, and III trial structures, placebo controls, double-blinding, and the concept of a primary endpoint with pre-specified statistical criteria all gained their regulatory weight from the efficacy requirement the Kefauver-Harris legislation imposed.
Key People
- Estes Kefauver — U.S. Senator from Tennessee who sponsored the amendments
- Oren Harris — U.S. Representative who co-sponsored the House version
- Frances Kelsey — FDA reviewer whose rejection of thalidomide catalyzed the legislation
- James Goddard — FDA Commissioner who enforced the new efficacy standards in the late 1960s
Public Law 87-781, U.S. Congress, 1962
Related landmarks
- 1964 · Declaration of Helsinki (Research Methods & Ethics)
- 1972 · Cochrane, 'Effectiveness and Efficiency' (Research Methods & Ethics)
- 1972 · Tuskegee Syphilis Study Exposed (Research Methods & Ethics)
- 1948 · MRC Streptomycin Trial for Pulmonary Tuberculosis (Research Methods & Ethics)